^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    20h
    SAVANNAH: Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (clinicaltrials.gov)
    P2, N=367, Active, not recruiting, AstraZeneca | Trial completion date: May 2025 --> Dec 2026
    Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET overexpression
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    22h
    Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (clinicaltrials.gov)
    P2, N=80, Recruiting, Stanford University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement • ROS1 rearrangement • EGFR positive
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel
    1d
    Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Second Affiliated Hospital of Nanchang University
    New trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab)
    1d
    Synthesis of 4-chloro-N'-(2-cyanoacetyl)benzohydrazide derivatives, cytotoxicity, VEGFR-2/EGFRT790M bioassays and in silico docking/ADMET studies. (PubMed, Bioorg Chem)
    Cytotoxic effects on A549 cell lines, compared to sorafenib (4.04 μM) and erlotinib (5.49 μM), showed that compounds 4, 5, 6, 7, 8, 10 and 11 with the IC50 values of 5.50-8.00 μM exhibited very high activities. Molecular docking was carried out for all derivatives to show their binding affinities and orientations inside the active sites of VEGFR-2 and EGFRT790M receptors to support the in vitro results. The data obtained from docking is highly matched with that obtained from biological testing.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    EGFR mutation • EGFR T790M
    |
    erlotinib • sorafenib
    2d
    RESCUE: Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC (clinicaltrials.gov)
    P2, N=118, Recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Not yet recruiting --> Recruiting | N=80 --> 118 | Trial completion date: Feb 2030 --> Feb 2032 | Trial primary completion date: Feb 2028 --> Feb 2030
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation
    2d
    An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=59, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • itacitinib (INCB039110) • simmitinib (SYHA1817)
    2d
    NeoLazer: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Yonsei University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    carboplatin • pemetrexed • Lazcluze (lazertinib)
    2d
    PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance. (PubMed, Thorac Cancer)
    High PD-L1 expression in EGFRm NSCLC is associated with more aggressive morphologic features and modifies the association between post-progression ICI and survival. These findings support PD-L1-informed selection after EGFR-TKI failure, while prospective confirmation is needed.
    Retrospective data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression
    2d
    Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib. (PubMed, Front Pharmacol)
    After multi-disciplinary treatment, the patient received concurrent chemoradiotherapy with pemetrexed and cisplatin, and achieved partial response. This patient did not receive durvalumab immunoconsolidation therapy for economic reasons...Patients with EGFR S768I/V769L compound mutated NSCLC may benefit from afatinib and osimertinib. Drugs with strong brain penetration capabilities are still needed for patients with S768I/V769L compound mutation to further improve survival outcomes.
    Journal • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR S768I
    |
    cisplatin • Tagrisso (osimertinib) • Gilotrif (afatinib) • Imfinzi (durvalumab) • pemetrexed • simmitinib (SYHA1817)
    2d
    Radiotherapy combined with third-generation EGFR tyrosine kinase inhibitor in first-line treatment of advanced oligometastatic non-small cell lung cancer: a single-center, retrospective study. (PubMed, J Thorac Dis)
    RT-related adverse events (AEs) (radiation pneumonitis, esophagitis, and cerebral edema) were all grade ≤2. RT (BED10 ≥50 Gy) combined with third-generation EGFR-TKI therapy improved PFS with favorable safety in EGFR-mutant advanced oligometastatic NSCLC.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    2d
    Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study. (PubMed, J Thorac Dis)
    For patients with EGFR-mutated NSCLC who develop resistance after treatment with third-generation EGFR TKIs, flumonertinib monotherapy during rechallenge treatment is a viable therapeutic option. Initiating treatment with flumonertinib earlier may lead to better survival outcomes, and thus further investigation of this strategy is warranted.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation